HanYu Pharmaceutical: Net Profit for First Three Quarters of Year Expected to Rise 503%-531% YoY

36Kr reports that HanYu Pharmaceutical announced its net profit attributable to shareholders for the first three quarters of 2026 is expected to be between 430 million and 450 million yuan, representing a year-over-year increase of 502.65%-530.68%. During the reporting period, the company's active pharmaceutical ingredient business continued to expand, driving growth in both revenue and profits. Meanwhile, R&D investment in the company's three-target innovative drug HY3003 and small nucleic acid projects increased significantly year-over-year.